bioRxivPharmacology & Toxicology
Jianpi Jiedu Recipe inhibits proliferation through reactive oxygen species-induced incomplete autophagy and reduces PD-L1 expression in colon cancer
L. Cheng, L. Xu, H. Yuan, Q. Zhao, W. Yue, S. Ma, X. Wu, D. Gu, Y. Sun, H. Shi, J. Xu
Abstract
BackgroundJianpi Jiedu Recipe has been used to treat digestive tract tumors in China since ancient times, and its reliability has been proven by clinical research. Currently, the specific biological mechanism of JPJDR in treating tumors is unclear. MethodologyCCK-8 assay was used to detect cell viability. Clone formation assay and EdU assay were used to detect cell proliferation potential. DCFH-DA probe and JC-1 probe were used to detect total intracellular reactive oxygen species and mitochondrial membrane potential, respectively. Western blotting and immunofluorescence were used to detect protein expression level and subcellular localization of cells. RFP-GFP-LC3B reporter system was used to observe the type of autophagy in cells. Xenograft tumor model was used to study the therapeutic effect of JPJDR in vivo. ResultsJPJDR has a good inhibitory effect on various colorectal cancer cells and effectively reduces the proliferation ability of HT29 cells. After treatment with JPJDR, the amount of reactive oxygen species in HT29 cells increased significantly and the mitochondrial membrane potential decreased. JPJDR induced the accumulation of autophagosomes in HT29 cells and was shown to be incomplete autophagy. At the same time, JPJDR reduced the expression of PD-L1.Meanwhile, JPJDR can exert a good therapeutic effect in xenograft tumor mice. ConclusionJPJDR is a low-toxic and effective anti-tumor agent that can effectively treat colon cancer in vitro and in vivo. Its mechanism may be through inducing mitochondrial dysfunction and incomplete autophagy injury to inhibit the proliferation of colon cancer cells.
- organism: human
- assay: proteomics
- research focus: cancer & tumor microenvironment
- approach: experimental assay
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Rigosertib promotes anti-tumor immunity via autophagic degradation of PD-L1 in colorectal cancer cells
- Fucoidan from brown algae Laminaria japonica trigger apoptosis in colon cancer cells
Koya Shimabukuro, Ikuko Miyagi, Nanae Harashima·bioRxiv·Jun 3, 2026
- Synergistic Antitumor Activity of SUMO1 degrader and Oxaliplatin through G6PD Inhibition in Colorectal Cancer
Sung Han Jung, Rakhim Roy, … Anita C. Bellail·bioRxiv·Apr 8, 2025
- Autophagy mediates cancer cell resistance to doxorubicin induced by the Programmed Death 1/Programmed Death Ligand 1 immune checkpoint axis
L. Minassian, D. Sanwalka, … C. H. Graham·bioRxiv·Jan 17, 2023
- Vertical inhibition of the autophagy pathway impairs growth and enhances sensitivity to mTORC1 inhibition in pancreatic ductal adenocarcinoma
Mallory K. Roach, Seamus E. Degan, … Kirsten L. Bryant·bioRxiv·Jun 29, 2026
- REDD1 is a determinant of the sensitivity of renal cell carcinoma cells to autophagy inhibition that can be therapeutically exploited by targeting PIM kinase activity
Jennifer S. Carew, Claudia M. Espitia, … Steffan T. Nawrocki·Cancer LettersPeer-reviewed·Jan 30, 2025